Halozyme elects Barbara Duncan to Board of Directors; Audit Committee assignment

HALOZYME THERAPEUTICS, INC.

Barbara Duncan elected to Board on Feb 3, 2023, with term expiring at 2024 annual meeting.
Initially assigned to serve on the Audit Committee.
Compensation follows non-employee director program; no related-party transactions disclosed.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Barbara Duncan

Director

HALO · HALOZYME THERAPEUTICS, INC.

Effective: 2023-02-03
Filed: February 6, 2023, 6:59 PM ET

On February 3, 2023, Barbara Duncan was elected to the Board of Directors of Halozyme Therapeutics, Inc.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Barbara Duncan was elected as Director at HALOZYME THERAPEUTICS, INC..

Action: elected
Role: Director

Exact text from the filing

On February 3, 2023, Barbara Duncan was elected to the Board of Directors of Halozyme Therapeutics, Inc.

View on SEC.gov

HALOZYME THERAPEUTICS, INC. filing history →

Source: SEC EDGAR

accession 0001159036-23-000006

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.